1[1]Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ) final report[J].Circulation,2002,106(25):3143-3142. 被引量：1
2[2]Gotto AM Jr,Whitney E,Stein EA,et al.Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex-CAPS)[J].Circulation,2000,101(5):477-484. 被引量：1
3[3]Kleemann R,Princen HM,Emeis JJ,et al.Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE-Lei-den transgenic mice:evidence for antiinflammatory effects of rosuvastatin[J].Circulation,2003,108 (11):1368-1374. 被引量：1
4[4]Albert MA,Danielson E,Rifai N,et al.Effect of statin therapy on C-reactive protein levels.,the pravastatin inflammation/CRP evaluation (PRINCE):a randomized trial and cohort study[J].JAMA,2001,286(1):64-70. 被引量：1
5[5]Ridker PM,Cannon CP,Morrow D,et al.C-reactive protein levels and outcomes after statin therapy[J].N Engl J Med,2005,352(1):20-28. 被引量：1
7[7]Ridker PM,JUPITER Study Group.Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity Creactive protein:rationale and design of the JUPITER trial[J].Circulation,2003,108(19):2292-2297. 被引量：1
8[8]von Haehling S,Anker SD,Bassenge E.Statins and the role of nitric oxide in chronic heart failure[J].Heart Fail Rev,2003,8(1):99-106. 被引量：1
9[9]Liao JK.Beyond lipid lowering:the role of statins in vascular protection[J].Int J Cardiol,2002,86(1):5-18. 被引量：1
10[10]Laufs U,Gertz K,Huang P,et al.Atorvastatin upregulates type Ⅲ nitric oxide synthase in thromhocytes,decreases platelet activation,and protects from cerebral ischemia in normocholesterolemic mice[J].Stroke,2000,31(10):2442-2449. 被引量：1
